Browse

Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization in Lipid Keratopathy

Cited 33 time in Web of Science Cited 34 time in Scopus
Authors
Oh, Joo Youn; Kim, Mee Kum; Wee, Won Ryang
Issue Date
2009-10
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Citation
CORNEA; Vol.28 9; 1070-1073
Keywords
bevacizumabcorneaneovascularizationlipid keratopathy
Abstract
Purpose: The purpose of this study was to evaluate the efficacy and safety of subconjunctival and corneal intrastromal bevacizumab injections on corneal neovascularization in patients with lipid keratopathy. Methods: Three eyes of 3 patients with lipid keratopathy accompanied by corneal neovascularization received at least 2 subconjunctival and corneal intrastromal injections of bevacizumab (1.25 mg/0.05 mL, respectively) at 1-month intervals. Ophthalmic examinations, including visual acuity, tonometry; slit lamp biomicroscopy, and corneal topography, were performed before injection and every month thereafter. Results: All patients had marked regression of corneal neovascularization. Reduction in lipid deposition was noted in one patient. There were no adverse ocular or systemic events, except for a small intracorneal hemorrhage noted in one patient, which quickly and spontaneously cleared. Conclusion: Subconjunctival and intracorneal bevacizumab is a well-tolerated and effective method for obliterating corneal neovascularization in lipid keratopathy.
ISSN
0277-3740
Language
English
URI
http://hdl.handle.net/10371/77959
DOI
https://doi.org/10.1097/ICO.0b013e31819839f9
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Ophthalmology (안과학전공)Journal Papers (저널논문_안과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse